Insight

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah and Vania Hungria

Oct 26, 2024, 12:33

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, shared an article by Vania Hungria, Department of hematology at Santa Casa de São Paulo, on X:

” Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?”

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Authors: Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, D.Phil and Ana Carolina Ribas de Almeida

Al-Ola A Abdallah

Al-Ola A Abdallah Ana Carolina Ribas de Almeida cancer Christopher Ward combination therapy D.Phil Marek Hus Myeloma OncoDaily Oncology P. Joy Ho Pawel Robak Santa Casa de São Paulo University of Kansas Medical Center Vania Hungria Vera Zherebtsova

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer